Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma

Bavbek, Sevim; Pur Ozyigit, Leyla; Ozturk, Ayse Bilge

doi:10.5152/TurkThoracJ.2019.180204

Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma

Leyla PUR ÖZYİĞİT, (Koç Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İmmünoloji ve Alerji Anabilim Dalı, İstanbul, Türkiye)

Ayşe Bilge ÖZTÜRK, (Koç Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İmmünoloji ve Alerji Anabilim Dalı, İstanbul, Türkiye)

Sevim BAVBEK (Ankara Üniversitesi, Tıp Fakültesi, İmmünoloji ve Alerji Bilim Dalı, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Turkish Thoracic Journal

6 1

Yıl: 2020 Cilt: 21 Sayı: 1 Sayfa Aralığı: 61 - 68 Metin Dili: İngilizce DOI: 10.5152/TurkThoracJ.2019.180204 İndeks Tarihi: 11-12-2020

Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma

Öz:

Improved knowledge about the pathogenesis of asthma has facilitated the development of novel drugs and provided hope for patientswith severe asthma. After the short- and long-term success of omalizumab in severe allergic phenotype, researchers have targeted patients with severe eosinophilic asthma who comprise up to 45% of adult severe asthma. Interleukin (IL)-5 and IL-5 receptor subunit α playcrucial roles in the development, maturation, and operation of eosinophils. Currently, patients treated with anti-IL-5 biologicals depletingeosinophils experience the positive efficacy of these drugs, especially with regard to the reduction of exacerbation rate. The aim of thisreview was to shed light on severe eosinophilic asthma treatment with these new currently available agents selectively targeting IL-5 orits receptor, discussing their usage including pre-treatment concerns, such as selecting the target population and choosing the right agentamong them, and subsequent assessment of relevant effect and safety issues.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract 2015;3:167-74. [CrossRef]
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Revised asthma guidelines 2019. Available at: https://ginasthma.org/wp-content/ uploads/2019/01/2010-GINA.pdf. Last accessed: 13 May 2019.
3. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062- 71. [CrossRef]
4. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73. [CrossRef]
5. Rackemann FM. A working classification of asthma. Am J Med 1947;3:601-6. [CrossRef]
6. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-95. [CrossRef]
7. Zervas E, Samitas K, Papaioannou AI, et al. An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Res 2018;4:DOI:10.1183/23120541.00125-2017. [CrossRef]
8. Pavord ID, Hilvering B, Shrimanker R. Emerging Biologics in Severe Asthma. Immunol Allergy Clin North Am 2016;36:609-23. [CrossRef]
9. Molfino NA, Gossage D, Kolbeck R, et al. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2012;42:712-37. [CrossRef]
10. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-36. [CrossRef]
11. Gleich GJ, Klion AD, Lee JJ, Weller PF. The consequences of not having eosinophils. Allergy 2013;68:829-35. [CrossRef]
12. van Veen IH, Ten Brinke A, Gauw SA, et al. Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol 2009;124:615-7. [CrossRef]
13. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9. [CrossRef]
14. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-207. [CrossRef]
15. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoidsparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189-97. [CrossRef]
16. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017;5:390-400. [CrossRef]
17. Powell C, Milan SJ, Dwan K, et al. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev 2015:CD010834. [CrossRef]
18. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302.htm, (2015).
19. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nucala#overview-section, (2015).
20. Available from: http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/003860/smops/Positive/human_smop_001336.jsp&mid=WC0b01ac058001d127, (2018).
21. Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol 2014;133:921-3. [CrossRef]
22. Roufosse F. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma. Front Med (Lausanne) 2018;5:49. [CrossRef]
23. Khatri S, Moore W, Gibson PG, et al. Assessment of the longterm safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 2019;143:1742-51.e7. [CrossRef]
24. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167:1655-9. [CrossRef]
25. Bagnasco D, Ferrando M, Varricchi G, et al. Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. Front Med (Lausanne) 2017;4:135. [CrossRef]
26. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125-32. [CrossRef]
27. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3:355-66. [CrossRef]
28. Brusselle G, Germinaro M, Weiss S, Zangrilli J. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther 2017;43:39- 45. [CrossRef]
29. Teva Respiratory LLC. CINQAIR® (reslizumab) injection, for intravenous use. Highlights of prescribing information, (2016).
30. Murphy K, Jacobs J, Bjermer L, et al. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract 2017;5:1572-81.e3. [CrossRef]
31. Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weightadjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab. Am J Respir Crit Care Med 2018;197:38-46. [CrossRef]
32. Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013;132:1086-96.e5. [CrossRef]
33. Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010;125:1237-44.e2. [CrossRef]
34. Ghazi A, Trikha A, Calhoun WJ. Benralizumab--a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cellmediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther 2012;12:113-8. [CrossRef]
35. Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med 2015;33:14- 20. [CrossRef]
36. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebocontrolled phase 3 trial. Lancet 2016;388:2115-27. [CrossRef]
37. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an antiinterleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-41. [CrossRef]
38. Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med 2017;376:2448-58. [CrossRef]
39. Prescribing information for Fasenra (benralizumab). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2017/761070s000lbl.pdf (2017).
40. Ferguson GT, Mansur AH, Jacobs JS, et al. Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma. J Asthma Allergy 2018;11:63-72. [CrossRef]
41. Bahadori K, Doyle-Waters MM, Marra C, et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009;9:24. [CrossRef]
42. Haldar P. Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma. Biologics 2017;11:81-95. [CrossRef]
43. Yancey SW, Keene ON, Albers FC, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol 2017;140:1509- 18. [CrossRef]
44. (NICE). NIfHaCE. Mepolizumab for treating severe refractory eosinophilic asthma. Available from: https://wwwniceorguk/ guidance/ta431 2017.
45. Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev 2017;9:CD010834. [CrossRef]
46. Cabon Y, Molinari N, Marin G, et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy 2017;47:129-38. [CrossRef]
47. Busse W, Chupp G, Nagase H, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. J Allergy Clin Immunol 2019;143:190-200.e20. [CrossRef]
48. Matucci A, Vultaggio A, Maggi E, Kasujee I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respir Res 2018;19:113. [CrossRef]
49. Ozturk AB, Sönmez SC, Göğebakan E, Özyiğit LP, Çağlayan B. Well Known and Unknown Asthma Phenotype: Allergic Asthma. EMJ Allergy Immunol 2019;4:76-87.
50. Buhl R, Humbert M, Bjermer L, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J 2017;49:pii: 1700634. [CrossRef]
51. Drick N, Seeliger B, Welte T, et al. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response. BMC Pulm Med 2018;18:119. [CrossRef]

APA	Pur Ozyigit L, Ozturk A, Bavbek S (2020). Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. , 61 - 68. 10.5152/TurkThoracJ.2019.180204
Chicago	Pur Ozyigit Leyla,Ozturk Ayse Bilge,Bavbek Sevim Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. (2020): 61 - 68. 10.5152/TurkThoracJ.2019.180204
MLA	Pur Ozyigit Leyla,Ozturk Ayse Bilge,Bavbek Sevim Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. , 2020, ss.61 - 68. 10.5152/TurkThoracJ.2019.180204
AMA	Pur Ozyigit L,Ozturk A,Bavbek S Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. . 2020; 61 - 68. 10.5152/TurkThoracJ.2019.180204
Vancouver	Pur Ozyigit L,Ozturk A,Bavbek S Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. . 2020; 61 - 68. 10.5152/TurkThoracJ.2019.180204
IEEE	Pur Ozyigit L,Ozturk A,Bavbek S "Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma." , ss.61 - 68, 2020. 10.5152/TurkThoracJ.2019.180204
ISNAD	Pur Ozyigit, Leyla vd. "Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma". (2020), 61-68. https://doi.org/10.5152/TurkThoracJ.2019.180204

APA	Pur Ozyigit L, Ozturk A, Bavbek S (2020). Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. Turkish Thoracic Journal, 21(1), 61 - 68. 10.5152/TurkThoracJ.2019.180204
Chicago	Pur Ozyigit Leyla,Ozturk Ayse Bilge,Bavbek Sevim Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. Turkish Thoracic Journal 21, no.1 (2020): 61 - 68. 10.5152/TurkThoracJ.2019.180204
MLA	Pur Ozyigit Leyla,Ozturk Ayse Bilge,Bavbek Sevim Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. Turkish Thoracic Journal, vol.21, no.1, 2020, ss.61 - 68. 10.5152/TurkThoracJ.2019.180204
AMA	Pur Ozyigit L,Ozturk A,Bavbek S Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. Turkish Thoracic Journal. 2020; 21(1): 61 - 68. 10.5152/TurkThoracJ.2019.180204
Vancouver	Pur Ozyigit L,Ozturk A,Bavbek S Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. Turkish Thoracic Journal. 2020; 21(1): 61 - 68. 10.5152/TurkThoracJ.2019.180204
IEEE	Pur Ozyigit L,Ozturk A,Bavbek S "Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma." Turkish Thoracic Journal, 21, ss.61 - 68, 2020. 10.5152/TurkThoracJ.2019.180204
ISNAD	Pur Ozyigit, Leyla vd. "Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma". Turkish Thoracic Journal 21/1 (2020), 61-68. https://doi.org/10.5152/TurkThoracJ.2019.180204